This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koshy, M. C. Articles by Blaufox, M. D. Search for Related Content PubMed PubMed Citation Articles by Koshy, M. C. Articles by Blaufox, M. D.

Circulation, Vol 55, 533-537, Copyright © 1977 by American Heart Association

ARTICLES

Physiologic evaluation of a new antihypertensive agent: prazosin HCl

MC Koshy, D Mickley, J Bourgiognie and MD Blaufox

The mechanism of action of prazosin hydrochloride, a new antihypertensive agent was studied in 14 patients with essential hypertension. Mean supine blood pressure for the group fell from 148/102 +/- 3/2 (SE) mm Hg at baseline to 139/91 +/- 5/4 after eight weeks of therapy (P less than 0.05). No significant postural hypotension was noted in the patients who responded to therapy. Glomerular filtration rate (endogenous creatinine or inulin clearance) and effective renal plasma flow (PAH clearance) remained unchanged during therapy as did supine and stimulated peripheral plasma renin activity. Cardiac output did not change significantly although plasma volume increased in ten out of 12 patients in whom it was measured (P less than 0.025). Among the patients whose mean blood pressure fell 10 mm Hg or more, peripheral vascular resistance fell significantly (P less than 0.025), and the change in plasma volume was not statistically significant. Among the patients whose mean blood pressure changed less than 10 mm Hg with therapy, there was no significant change in peripheral vascular resistance and plasma volume increased significantly (P less than 0.025). Prazosin hydrochloride appears to be an effective antihypertensive agent which acts by peripheral vasodilatation. It may cause fluid retention. The drug does not appear to affect renal function or renin secretion.

This article has been cited by other articles:

				R. P. Blankfield Fluid Matters in Choosing Antihypertensive Therapy: A Hypothesis That the Data Speak Volumes J Am Board Fam Med, March 1, 2005; 18(2): 113 - 124. [Abstract] [Full Text] [PDF]

				A. F. Khoury and N. M. Kaplan {alpha}-Blocker Therapy of Hypertension: An Unfulfilled Promise JAMA, July 17, 1991; 266(3): 394 - 398. [Abstract] [PDF]

				J. L. Holtzman, P. M. Kaihlanen, J. A. Rider, A. J. Lewin, J. S. Spindler, and J. A. Oberlin Concomitant Administration of Terazosin and Atenolol for the Treatment of Essential Hypertension Arch Intern Med, March 1, 1988; 148(3): 539 - 543. [Abstract] [PDF]

				E. D. Frohlich, R. A. Cooper, and E. J. Lewis Review of the Overall Experience of Captopril in Hypertension Arch Intern Med, July 1, 1984; 144(7): 1441 - 1444. [Abstract] [PDF]

				J. H. Bauer, L. B. Jones, and P. Gaddy Effects of Prazosin Therapy on BP, Renal Function, and Body Fluid Composition Arch Intern Med, June 1, 1984; 144(6): 1196 - 1200. [Abstract] [PDF]

				J. H. Bauer, L. B. Jones, and P. Gaddy Effects of Indoramin Therapy on BP, Renal Function, and Body Fluid Composition Arch Intern Med, February 1, 1984; 144(2): 308 - 312. [Abstract] [PDF]

				W. S. COLUCCI Alpha-Adrenergic Receptor Blockade with Prazosin: Consideration of Hypertension, Heart Failure, and Potential New Applications Ann Intern Med, July 1, 1982; 97(1): 67 - 77. [Abstract] [PDF]

				R. D. MAGORIEN, D. W. TRIFFON, C. E. DESCH, W. H. BAY, D. V. UNVERFERTH, and C. V. LEIER Prazosin and Hydralazine in Congestive Heart Failure: Regional Hemodynamic Effects in Relation to Dose Ann Intern Med, July 1, 1981; 95(1): 5 - 13. [Abstract] [PDF]